

Blackfinch Adapt AIM Growth Portfolio

Performance

Q2 2023

GROWTH INVESTOR
 2020 IAWARDS

WINNER
 BEST BR
 INVESTMENT
 MANAGER (LISTED)

The Adapt AIM Portfolios are a Discretionary Portfolio Management Service designed with the aim of mitigating Inheritance Tax (IHT) by investing in a portfolio of AIM-listed shares, carefully constructed by our team of specialist investment managers.

Blackfinch act as Discretionary Investment Managers for the service and are assisted by Chelverton Asset Management, the award winning fund managers with proven expertise of investment in AIM. Chelverton act as Investment Advisers to Blackfinch and assist with stock selection, due diligence and portfolio construction.

Performance**

Total returns only and do not take into account fees. Figures are for illustrative purposes only and are based on model portfolio returns.

Calculated by FactSet

	Q2 2023	Since Portfolio Inception ⁴
Adapt AIM Growth Portfolio	-1.9%	75.9%
Numis Alternative Markets Total Return ⁵	-5.5%	17.0%
Annualised Volatility	3 year	Since Portfolio Inception ⁴
Standard Deviation	12.2%	13.4%
Numis Alternative Markets Total Return Standard Deviation ⁵	12.3%	13.3%
Sharpe Ratio	0.17	0.55
Numis Alternative Markets Total Return Sharpe Ratio ⁵	-0.44	0.10
Forward P/E Ratio⁶	14.4	

About

Launch Date	June 2016
Product Type	Discretionary
Minimum Investment	£15,000

Portfolio Information¹

Initial Fee	0%
Management Fee	1.5% + VAT
Dividend Yield ²	2.6%*

Key Features

Simple tax planning strategy targeting IHT exemption after 2 years

Eligible for an ISA; combining the tax benefits of an ISA with targeted IHT relief

Access to the experienced and acclaimed fund management team at Chelverton

Access to capital at all times (subject to market liquidity)

Focus on delivering capital growth

Low minimum investment amount offering IHT relief to a wider audience of investors

Available Platforms³



¹See rate card for full details of current fees

²Based on quarter end values and model portfolio weightings. Calculated by FactSet.

³Fee structure may vary according to choice of platform

⁴24/06/2016

⁵Source: Numis via FactSet

⁶Forecast FY1 figure based on model portfolio weightings at quarter end. Calculated by FactSet.

Portfolio Commentary

With concerns about the banking crisis easing at the start of the quarter, markets moved upwards. This trend continued through the period, particularly in the US, where excitement about the potential of Artificial Intelligence drove up the share prices of some big tech stocks. Fears that political in-fighting would result in a stalemate in US debt ceiling negotiations – thereby risking a US debt default – were also allayed after an eleventh-hour resolution was reached. However, the macro-economic narrative was once again dominated by the ongoing strength of inflation. While the US Federal Reserve (Fed) took the opportunity to pause rate rises in June, both the Fed and the European Central Bank ended the quarter commenting that rates had to move higher. In the UK, the picture was more negative, as sticky inflation (including a rise in core inflation in June) led the Bank of England to hike rates by 25 basis points (bps) in May and a further 50bps in June. This left interest rates at the end the quarter at 5.0%, with expectations that rates would need to be higher and for longer. This unwelcome news was reflected in a weak May and June for UK markets. Further afield, China's post-pandemic economic recovery has been weaker than expected, dampening optimism that it would help buoy the global economy. On a positive note, domestically, the UK consumer remains resilient, with a strong labour market, wage inflation and drawdown of pandemic-related savings, while company earnings reports have remained broadly in line with analyst expectations. Furthermore, the UK continues to trade at a material discount to global equities.

The portfolio was down in the quarter, albeit to a lesser extent than the market. We continue to see investee companies pursue growth, both through internal initiatives and bolt-on acquisitions, which should stand the portfolio in good stead over the medium term.

For the second quarter of 2023, the Growth Portfolio performance was underpinned by positive gains from Iomart (+38.9%) and Craneware (+18.7%), whilst Alliance Pharma (-26.1%) and GB Group (-22.4%) detracted from performance.

Alliance Pharma, the international healthcare business, was down in the period. It announced expected profit before tax to be marginally below expectations. While the company was trading in-line from a revenue and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortisation) perspective, the strengthening of the pound versus the dollar and the rising interest rate environment had an adverse impact on expectations.


GB Group, the global identity verification and fraud prevention specialist, also declined in the period. Brokers downgraded forecasts following the company's full-year results. While strong growth was achieved in its Location and Fraud Segments, the Identity segment experienced headwinds, predominantly in the US, with lengthening sales cycles and project delays resulting in a non-cash impairment charge.

Iomart, the cloud computing and IT managed services company, performed well in Q2. The company announced full-year results in line with expectations, organic growth from its cloud managed services, the acquisition of Extrinsic (boosting its Microsoft Azure expertise) and an in-line outlook statement.

Craneware, a leading value cycle software provider for the healthcare industry, was also strong. The company announced a share buyback programme of £5m and made a statement that it didn't believe the company's market price reflected the potential of its market opportunity.

Buy List Changes: Two additions were made to the buy list in the quarter, namely Accesso Technology, the software solutions company focused on the attractions and leisure industry, and Focusrite, the international music and audio products company.


Exposure by Sector^{1,2}



Banking	3.6%
Biopharmaceuticals	3.6%
Business Services	25.0%
Food and Tobacco Production	7.1%
Hardware	14.3%
Healthcare Equipment	3.6%
Healthcare Services	10.7%
Industrial Manufacturing	3.6%
Industrial Services	3.6%
Real Estate	3.6%
Software and Consulting	14.3%
Telecommunications	3.6%
Hospitality Services	3.6%

Exposures by Underlying Company Size (£m)¹

The Growth Portfolio currently contains 28 equally weighted stocks with an average market capitalisation of £364.6 million.



£0-£100m	10.7%
£100m - £250m	32.1%
£250m - £500m	35.7%
£500m - £1bn	14.3%
£1bn+	7.1%

¹Percentage may not total 100% due to rounding
²Source: FactSet

Performance**

Figures are for illustrative purposes only and are based on model portfolio returns.


	Quarter	YTD	2 Year	3 Year	5 Year	Since Inception ³	Calendar Year				
							2022	2021	2020	2019	2018
Adapt AIM Growth Portfolio ¹	-1.9%	-9.1%	-25.0%	10.8%	7.7%	75.9%	-20.3%	20.4%	10.9%	28.5%	-12.2%
Numis Alternative Markets - Total Return ²	-5.5%	-8.2%	-37.7%	-11.4%	-24.8%	17.0%	-31.1%	7.6%	19.3%	14.7%	-17.5%

Discrete Yearly Performance to Quarter End

	01/07/2022 30/06/2023	01/07/2021 30/06/2022	01/07/2020 30/06/2021	01/07/2019 30/06/2020	01/07/2018 30/06/2019
Adapt AIM Growth Portfolio ¹	-12.1%	-14.6%	47.7%	1.9%	-4.6%
Numis Alternative Markets - Total Return ²	-12.9%	-28.5%	42.2%	-3.3%	-12.2%

Past performance cannot be taken as a guarantee of future performance. Please read the disclaimer at the end of this page.

Performance since Launch



█	Adapt AIM Growth Portfolio ¹
█	Numis Alternative Markets - Total Return ²

¹ Calculated by FactSet. Total returns and do not take into account fees.

² Source: Numis via FactSet

³ 24/06/2016

Financial data and analytics provider FactSet

IMPORTANT INFORMATION

Capital At Risk. This performance sheet is being issued by Blackfinch Investments Limited (Blackfinch), which is authorised and regulated by the Financial Conduct Authority (FCA number 153860). Registered address: 1350–1360 Montpellier Court, Gloucester Business Park, Gloucester, GL3 4AH. Registered in England and Wales Company Number 02705948.

Past performance cannot be taken as a guarantee of future performance. This performance sheet is based on a model portfolio. No guarantee can be made as to the composition of any individual portfolio. All figures are correct at the time of compilation. Any decision to invest in this service should not be based on this performance sheet but rather made on the basis of the information contained in the brochure, and the terms and conditions. Prospective investors must rely on their own examination of the legal, taxation, financial and other consequences of investing and the risk involved.

Prospective investors should not treat the contents of this fact sheet as advice relating to legal, taxation or other matters. If in any doubt about the proposal discussed in this paper, its suitability, or what action should be taken, the investor should consult their own professional advisers.

*Dividend yield reflects dividends received over a trailing 12-month period using end-of-period portfolio value.

**Total returns are used in order to give a clearer representation of the actual returns achieved, combining both the capital returns with income received from dividends.

FactSet calculate returns by compounding daily returns.

Data and analytics provided by FactSet except where otherwise stated.

Fees will be taken from the value of your investment.